The statement kickstarts the company’s product launch, which will focus on establishing a limited number of lead extraction training centres through its distribution partner, DVx. The SLS II is used for the removal of problematic pacemaker and defibrillator cardiac leads.
Chair, president and CEO Emile J Geisenheimer said "Japan represents a significant market opportunity for our products. Product reimbursement for our SLS II is an important accomplishment as it is our first product to have both regulatory and reimbursement approval in Japan. We look forward to offering our full portfolio of products in the future."
